Management of acromegaly: an exploratory survey of physicians from the Middle East and North Africa

• Published in: Hormones (Athens, Greece) Greece), 2018-09, Vol.17 (3), p.373-381
• Main Authors: Ahmad, Maswood M., Buhary, Badurudeen Mahmood, Al Mousawi, Fatima, Alshahrani, Fahad, Brema, Imad, Al Dahmani, Khalid M., Beshyah, Salem A., AlMalki, Mussa H.
• Format: Article
• Language: English
• Subjects: Acromegaly - diagnosis; Acromegaly - therapy; Africa, Northern; Endocrinology; Guideline Adherence - statistics & numerical data; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Internal Medicine - statistics & numerical data; Medicine; Medicine & Public Health; Metabolic Diseases; Middle East; Neurosurgeons - statistics & numerical data; Original Article; Physicians - statistics & numerical data; Physicians, Family - statistics & numerical data; Practice Guidelines as Topic
• ISSN: 1109-3099; 2520-8721
• DOI: 10.1007/s42000-018-0045-1

Background Worldwide variations exist in the diagnosis and management of patients with acromegaly. For such a rare condition, the knowledge and perception of physicians would most likely direct the care of patients. However, the adherence of physicians in non-Western regions to guidelines for the diagnosis and management of acromegaly has not been previously ascertained. Methods An online survey was conducted to assess the perceptions and practice of physicians regarding acromegaly diagnosis and management as per international guidelines. An electronic questionnaire containing key questions was mailed, initially to physicians in Saudi Arabia (KSA) and later to other countries in the Middle East and North Africa (MENA) region. Additional questions were included to ensure the relevance of the respondents’ replies. The responses were captured and summarized anonymously. Descriptive comparisons were made with two similar international and national surveys from other regions. Results Two hundred forty-seven doctors responded to the survey. Of these, 155 (64.5%) fulfilled the inclusion criteria and, in particular, confirmed having treated acromegaly patients in the previous 12 months, and they constituted the basis of this study. The three most common referring specialties for patients were internists (44; 28.4%), neurosurgeons (46; 29.6%), and family medicine physicians (42; 27.1%), respectively. The combination of growth hormone (GH) nadir during the oral glucose tolerance test (OGTT) and elevated insulin-like growth factor-1 (IGF-1) levels was used by 99 physicians (63.9%) to diagnose acromegaly. The main determinant for treatment choice was tumor mass characteristics confirmed by 117 respondents (75.5%) with neurosurgery as first treatment choice confirmed by 124 respondents (80%). Combined measurement of IGF-1 and GH levels after OGTT at 3 months after surgery was the most widely used criterion for assessment of surgical outcomes, confirmed by 82 physicians (52.9%). The biggest barriers to optimal management of acromegaly as perceived by 38.1% and 35.5% of the respondents were high cost of medications and lack of physicians’ awareness, respectively. Conclusions The majority of the surveyed physicians reported variable adherence to the international acromegaly guidelines. Clearly, higher awareness is needed among physicians for early diagnosis and timely referral for specialist management.